NASDAQ · Financial Statements
Corcept Therapeutics Incorporated (CORT) Financial Statements
$110.16
NASDAQ: CORT
Market Cap $11.91B
Overview Financials Dividend Corcept Therapeutics Incorporated most recently reported annual revenue of $761.0M, net profit of $100.0M. Revenue grew at an average annual rate of 16.5% over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Annual Financials (USD)
Metric 2021 2022 2023 2024 2025 Revenue $366.0M $402.0M $482.0M $675.0M $761.0M Operating Profit $124.0M $113.0M $107.0M $137.0M $45.0M Net Profit $113.0M $101.0M $106.0M $140.0M $100.0M EPS $0.89 $0.87 $0.94 $1.23 $0.82 Op Margin 34.0% 28.0% 22.2% 20.3% 5.9%
Balance Sheet (USD)
Metric 2021 2022 2023 2024 2025 Total Assets $424.0M $583.0M $622.0M $841.0M $837.0M Total Liabilities $48.0M $82.0M $115.0M $161.0M $189.0M Cash $78.0M $66.0M $136.0M $128.0M $120.0M Borrowings $1.0M $1.0M $0 $7.0M $6.0M
Cash Flow (USD)
Metric 2021 2022 2023 2024 2025 Operating Cash Flow $168.0M $120.0M $127.0M $198.0M $142.0M Investing Cash Flow $136.0M $-115.0M $91.0M $-180.0M $70.0M Financing Cash Flow $-303.0M $-17.0M $-149.0M $-38.0M $-220.0M Net Cash Flow $1.0M $-11.0M $69.0M $-8.0M $-7.0M Free Cash Flow $167.0M $120.0M $127.0M $196.0M $142.0M
Valuation & Return Ratios
Metric Value PEG Ratio -3.77 EV / EBITDA 429.14 FCF Yield 0.86% Quick Ratio 2.77 Interest Coverage — Return 1Y 63.86% Return 3Y 339.73% Return 5Y 474.91%
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer .